CompletedNCT06309277
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
This study evaluated the safety of GM-1020 for people with depression.
Medication studyAges 18–65United Kingdom
Understand this study
What did researchers investigate?
This study evaluated the safety of GM-1020 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- ManchesterSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: February 1, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 46
- Sponsor
- Gilgamesh Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06309277
- Official title
Show the full official title
A Two-Part Controlled Clinical Study to Evaluate Safety, Tolerability, Response, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of GM-1020 in Patients With Major Depressive Disorder
Recruitment & locations
CompletedManchester
Questions about this study
What did researchers investigate?
This study evaluated the safety of GM-1020 for people with depression.
Who is behind this study?
The study sponsor is Gilgamesh Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including GM-1020.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
(GluEsk) Glutamate and Esketamine
A definitive multi-centre pragmatic randomised controlled double-blind trial of the clinical and cost effectiveness of mirtazapine and sertraline versus placebo for the treatment of depression in d...